Research programme: skin disorders regenerative therapeutics - NuGene

Drug Profile

Research programme: skin disorders regenerative therapeutics - NuGene

Latest Information Update: 13 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuGene International
  • Developer NuGene BioPharma; NuGene International
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Collagen stimulants; Growth stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Burn infections; Burns
  • Research Acne; Scars; Wounds

Most Recent Events

  • 04 May 2015 Early research in Scars in USA (Topical)
  • 04 May 2015 Early research in Wounds in USA (Topical)
  • 04 May 2015 NuGene files for patent protection with US PTO for Burns, Scars, Wound healing bandages treated with nanoencapsulated human adipose derived stem cell culture in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top